200 related articles for article (PubMed ID: 25409876)
1. Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86.
Alao JP; Michlikova S; Dinér P; Grøtli M; Sunnerhagen P
BMC Cancer; 2014 Nov; 14():853. PubMed ID: 25409876
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.
Fenton MS; Marion KM; Salem AK; Hogen R; Naeim F; Hershman JM
Thyroid; 2010 Sep; 20(9):965-74. PubMed ID: 20629553
[TBL] [Abstract][Full Text] [Related]
4. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.
Kim DW; Jo YS; Jung HS; Chung HK; Song JH; Park KC; Park SH; Hwang JH; Rha SY; Kweon GR; Lee SJ; Jo KW; Shong M
J Clin Endocrinol Metab; 2006 Oct; 91(10):4070-6. PubMed ID: 16849418
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.
Spanheimer PM; Park JM; Askeland RW; Kulak MV; Woodfield GW; De Andrade JP; Cyr AR; Sugg SL; Thomas A; Weigel RJ
Clin Cancer Res; 2014 Apr; 20(8):2115-25. PubMed ID: 24526731
[TBL] [Abstract][Full Text] [Related]
6. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
7. XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway.
Lodyga M; De Falco V; Bai XH; Kapus A; Melillo RM; Santoro M; Liu M
Oncogene; 2009 Feb; 28(7):937-49. PubMed ID: 19060924
[TBL] [Abstract][Full Text] [Related]
8. Modification of PI3K- and MAPK-dependent chemotaxis in aortic vascular smooth muscle cells by protein kinase CbetaII.
Campbell M; Trimble ER
Circ Res; 2005 Feb; 96(2):197-206. PubMed ID: 15591231
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line.
Caccia D; Miccichè F; Cassinelli G; Mondellini P; Casalini P; Bongarzone I
Mol Cancer; 2010 Oct; 9():278. PubMed ID: 20955590
[TBL] [Abstract][Full Text] [Related]
10. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.
Drosten M; Hilken G; Böckmann M; Rödicker F; Mise N; Cranston AN; Dahmen U; Ponder BA; Pützer BM
J Natl Cancer Inst; 2004 Aug; 96(16):1231-9. PubMed ID: 15316058
[TBL] [Abstract][Full Text] [Related]
11. Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.
Nelson-Taylor SK; Le AT; Yoo M; Schubert L; Mishall KM; Doak A; Varella-Garcia M; Tan AC; Doebele RC
Mol Cancer Ther; 2017 Aug; 16(8):1623-1633. PubMed ID: 28500237
[TBL] [Abstract][Full Text] [Related]
12. Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.
Spanheimer PM; Cyr AR; Gillum MP; Woodfield GW; Askeland RW; Weigel RJ
Ann Surg; 2014 Apr; 259(4):793-9. PubMed ID: 24045439
[TBL] [Abstract][Full Text] [Related]
13. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
[TBL] [Abstract][Full Text] [Related]
14. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
[TBL] [Abstract][Full Text] [Related]
15. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells.
Gilad LA; Bresler T; Gnainsky J; Smirnoff P; Schwartz B
J Endocrinol; 2005 Jun; 185(3):577-92. PubMed ID: 15930183
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of RET tyrosine kinase by SU5416.
Mologni L; Sala E; Cazzaniga S; Rostagno R; Kuoni T; Puttini M; Bain J; Cleris L; Redaelli S; Riva B; Formelli F; Scapozza L; Gambacorti-Passerini C
J Mol Endocrinol; 2006 Oct; 37(2):199-212. PubMed ID: 17032739
[TBL] [Abstract][Full Text] [Related]
17. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
18. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
Akeno-Stuart N; Croyle M; Knauf JA; Malaguarnera R; Vitagliano D; Santoro M; Stephan C; Grosios K; Wartmann M; Cozens R; Caravatti G; Fabbro D; Lane HA; Fagin JA
Cancer Res; 2007 Jul; 67(14):6956-64. PubMed ID: 17638907
[TBL] [Abstract][Full Text] [Related]
19. Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.
Schweppe RE; Kerege AA; Sharma V; Poczobutt JM; Gutierrez-Hartmann A; Grzywa RL; Haugen BR
Thyroid; 2009 Aug; 19(8):825-35. PubMed ID: 19500021
[TBL] [Abstract][Full Text] [Related]
20. Preparation of 3-substituted-1-isopropyl-1H-pyrazolo[3,4-d]pyrimidin-4-amines as RET kinase inhibitors.
Dinér P; Alao JP; Söderlund J; Sunnerhagen P; Grøtli M
J Med Chem; 2012 May; 55(10):4872-6. PubMed ID: 22559926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
